A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

BACKGROUND: Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC). METHODS: Patients r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Y-K, Rha, S Y, Tassone, P, Barriuso, J, Yu, R, Szado, T, Garg, A, Bang, Y-J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134501/
https://www.ncbi.nlm.nih.gov/pubmed/24960402
http://dx.doi.org/10.1038/bjc.2014.356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134501/
https://www.ncbi.nlm.nih.gov/pubmed/24960402
http://dx.doi.org/10.1038/bjc.2014.356

Ejemplares similares